A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

Exclusion Criteria

• •Subjects must not have a systolic blood pressure above 145 milimeter(mm) of mercury(Hg) or a diastolic pressure above 85 mmHg at the screening visit.
• •History of breathing problems in adult life confirmed by normal lung function parameters (≥85% predicted).
• •Donation of more than 500 mL blood within a 56 day period.
• •Subjects who have suffered a lower respiratory tract infection within 4 weeks of the screening visit.
• •Current or chronic history of liver disease, or known hepatic or biliary abnormalities.
• •The subject treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness.
• •The subject has a positive: drug/alcohol, Hepatitis, HIV screen.
• •Abuse of alcohol.
• •Subject having positive cotinine and urine alcohol test.
• •Participated in \>3 clinical trials in the previous 10 months (if male), or \>2 clinical trials in the previous 10 months (if female), or the subject has participated in a study (including follow up) within 60 days prior to the first dosing day in the current study.
• •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
• •Taken systemic, oral or depot corticosteroids less than 12 weeks or inhaled, intranasal or topical steroids less than 4 weeks before the screening visit.
• •Use of prescription or non-prescription drugs.
• •History of severe milk protein allergy, sensitivity to any of the study medications, including immediate or delayed hypersensitivity to any intranasal, inhaled or systemic corticosteroid therapy.
• •Pregnant or lactating females.
• •Unwillingness or inability to follow the procedures outlined in the protocol.
• •Subject is mentally or legally incapacitated.